Can Fite Biopharma Ltd (CANF) FinancialsCANFCan Fite Biopharma Ltd

Evaluating the bottom line, Can Fite Biopharma Ltd maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2316.83%, while the net margin is -2277.72%. These profitability ratios, combined with a Return on Equity (ROE) of -211.37%, provide a clear picture of how effectively CANF converts its operational activities into shareholder value.

In the context of the broader market, CANF competes directly with industry leaders such as ABOS and ATYR. With a market capitalization of $4.91M, it holds a significant position in the sector. When comparing efficiency, CANF's gross margin of 100.00% stands against ABOS's N/A and ATYR's N/A. Such benchmarking helps identify whether Can Fite Biopharma Ltd is trading at a premium or discount relative to its financial performance.

Can Fite Biopharma has reported consistent total revenue of around 101,000 USD per quarter, but it has also shown significant net losses, with Q2 2026 reporting -2,300,500 USD. The gross margin remains high at 100%, but the overall financial health is concerning due to persistent losses and a negative net margin of -2277.72%.